NCT01986933View on ClinicalTrials.gov

A Phase 2 Study of CIM331 for Atopic Dermatitis Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

264

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

April 30, 2015

Study Completion Date

June 30, 2016

Conditions
Atopic Dermatitis
Interventions
DRUG

nemolizumab (CIM331)

OTHER

Placebo

Trial Locations (18)

10016

New York

23507

Norfolk

28226

Charlotte

29407

Charleston

29425

Charleston

30022

Alpharetta

33142

Miami

36207

Anniston

40202

Louisville

40217

Louisville

44106

Cleveland

46256

Indianapolis

48706

Bay City

60005

Arlington Heights

60612

Chicago

77845

College Station

92122

San Diego

97239

Portland

Sponsors
All Listed Sponsors
lead

Chugai Pharmaceutical

INDUSTRY

NCT01986933 - A Phase 2 Study of CIM331 for Atopic Dermatitis Patients | Biotech Hunter | Biotech Hunter